Major lung resection is one of the most common procedures performed in thoracic surgery, but
it may involve considerable bleeding and the occasional need for a transfusion and/or
reoperation for bleeding in specific cases. In addition, lysis of pleural-parenchymal
adhesions and dissection can represent a challenge in patients who have undergone
chemotherapy and/or radiation therapy, and in patients with bronchiectasis or COPD. Several
intraoperative methods have been used to manage blood loss, including topical haemostatic
agents, bipolar sealers or electrocautery. Transcollation technology (TT) consists of a
disposable bipolar sealer that uses a radiofrequency coagulation system to deliver a saline
solution that provides haemostatic sealing of soft tissue and bone and provides localized
cooling without charring. Blood loss reduction has been previously described in several
fields of surgery.
The primary end-point of the proposed trial is to assess if the ability of Transcollation
Technology in reducing the proportion of patients showing bleeding perioperatively within the
setting of a prospective randomized controlled trial.
The secondary end-point is to assess if Transcollation Technology is able to improve
postoperative outcomes reducing the length of hospital stay.